Even if the true incidence of hypoglycemia in type 2 diabetes mellitus (T2DM) remains difficult to estimate, with highly variable rates reported in the literature, it is likely more common than previously thought. While most hypoglycemic episodes in T2DM are considered "mild," they 
in which a patient is unable to self-treat, and thus requires the assistance of another person, making the data on severe hypoglycemia less subjective and, likely, more reliable. 1, 4 Mild hypoglycemic events, usually defined as self-treated episodes, are more common than severe hypoglycemia, but may be underreported since most patients do not spontaneously describe mild episodes at a physician/clinic visit, in part for fear of appearing unable to manage their condition. 1 Since patients may be unreliable and likely to underestimate the frequency with which they experience hypoglycemia, patients' relatives and partners should also be questioned, to provide a more accurate record of hypoglycemic episodes. 1, 5, 6 Despite these limitations, in recent 
Potential Link to Cardiovascular Morbidity and Mortality
Other concerns regarding the consequences of hypoglycemia are linked to cardiovascular morbidity and mortality. 24 Several mechanisms are potentially involved. Hypoglycemia has long been known as a risk factor for cardiac arrhythmia; [25] [26] [27] a recent study 28 showed that prior exposure to hypoglycemia led to impaired cardiovascular autonomic function, including decreased cardiac vagal baroreflex sensitivity, which may contribute to increased cardiovascular morbidity and mortality in patients with diabetes. Hypoglycemia has also been associated with cardiac ischemia 29, 30 and prothrombotic changes. patients also suggests some degree of glucose dependency. 65, 66 In contrast, a marked increase in the risk of hypoglycemia has been reported when GLP-1 analogs are combined with sulphonylureas, 70, 71 and a reduction in the dose of sulphonylurea is generally recommended to reduce this risk. For example, the incidence of hypoglycemia was 14% and 36% with exenatide 5 µg and 10 µg, respectively, added to sulphonylurea, compared to 3% for placebo added to sulphonylurea. 
REAL-LIFE EXPERIENCE
The hypoglycemia profile described with vildagliptin in clinical studies is further supported by results from a "real-world" study, in which 52 Muslim patients with T2DM in north west London, UK, were followed during the Ramadan fasting period (no food or drink consumed from sunrise to sunset for a lunar month).
Patients entered the observational period with 
